drugset / Trial / NCT07389733
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the safety, tolerability, efficacy and pharmacokinetics of HRS-6208 in combination with HRS-8080 ± HRS-6209, or in combination with fulvestrant ± HRS-6209, or in combination with letrozole ± HRS-6209 in patients with advanced unresectable or metastatic breast cancer.
Timeline
- Start
- 2026-03-27
- Primary completion
- 2028-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | — | — |
| Subject | HRS-6208 | Unknown | — | — |
| Subject | HRS-6209 | Small molecule | — | — |
| Subject | HRS-8080 | Unknown | — | — |
| Subject | Letrozole | Other / unclassified | — | — |